Tomasz Olczyk

University of Gdańsk

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Barbara Jarząb

The Maria Sklodowska-Curie National Research Institute of Oncology

Daria Handkiewicz-Junak

The Maria Sklodowska-Curie National Research Institute of Oncology

Aleksandra Kropińska

The Maria Sklodowska-Curie National Research Institute of Oncology

Jolanta Krajewska

The Maria Sklodowska-Curie National Research Institute of Oncology

Ewa Paliczka-Cieślik

The Maria Sklodowska-Curie National Research Institute of Oncology

Aleksandra Kukulska

State Higher Vocational School in Głogów

Józef Roskosz

The Maria Sklodowska-Curie National Research Institute of Oncology

Tomasz Gawlik

The Maria Sklodowska-Curie National Research Institute of Oncology

Aleksandra Ledwoń

The Maria Sklodowska-Curie National Research Institute of Oncology

Barbara Michalik

The Maria Sklodowska-Curie National Research Institute of Oncology

Cooperative Institutions

The Maria Sklodowska-Curie National Research Institute of Oncology

Centrum Onkologii

Medical University of Silesia

National Institute of Oncology

Polish Academy of Sciences

Jagiellonian University

Medical University of Lodz

Medical University of Warsaw

Instytut Biologii Doświadczalnej im. Marcelego Nenckiego

Silesian Center for Heart Disease

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Treatment with sorafenib in advanced thyroid cancer - a case report.

Endokrynologia Polska (2010)

Jolanta Krajewska Tomasz Olczyk Józef Roskosz Ewa Paliczk-Cieślik Aleksandra Kukulska Anetta Smietana

Papillary thyroid cancer (PTC) usually has a good prognosis. The treatment, including total thyroidectomy and complementary radioiodine (RAI) therapy, gives complete remission in 90% of patients. However, in 10% of subjects with metastatic disease, the prognosis is poor. In the group of patients with disease progression and no 131I uptake, searching for new therapeutic modalities before all tyrosine kinase inhibitors and other antiangiogenic agents is necessary. The study presents the case of a 55-year-old male with advanced PTC /pT3mNxMo/ diagnosed in 1993. Primary treatment by total thyroidectomy and 131I ablation led to complete remission. In 2000 local as well as lymph node recurrence was diagnosed and successively treated by surgery. In 2006 an increasing serum thyroglobulin level was noted and a single lung metastasis was diagnosed and operated on. In 2007 new foci in CNS and vertebral column with no 131I uptake were stated. Further progression (bones, CNS, and pterygoid muscle) was confirmed by PET-CT. The patient underwent neurosurgical metastasectomy twice and palliative CNS and vertebra's radiotherapy. Liver metastases were diagnosed in 2009. Treatment with increasing doses of thalidomide (up to 800 mg/d) was administered for 3 months with a good tolerance; however, the therapy was withdrawn due to cancer progression. Next, sorafenib (800 mg/d) was given for 16 weeks. Radiological examination performed after 16 weeks confirmed stable disease, whereas 2 months later, after sorafenib withdrawal due to lack of treatment possibility, further progression was observed. Metronomic chemotherapy with Adriamycin was instituted which gave disease stabilization for 6 months. The patient died with advanced disseminated disease due to pulmonary embolism. We present this case to document no adverse effects of therapy with sorafenib in a patient with brain DTC metastases. Sorafenib therapy was only short-term, but no progression occurred in this time.

Source

Cite

Citations (12)

Management of treatment-related toxicity caused by multi kinase inhibitors administered due to advanced thyroid carcinoma

Endocrine Abstracts (2017)

Jolanta Krajewska Aleksandra Kukulska Daria Handkiewicz-Junak Ewa Paliczka-Cieślik Tomasz Olczyk

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

10.1530/endoabs.49.ep1440

Cite

Citations (0)

Ekologia w edukacji religijnej z perspektywy religioznawczej

Karto-Teka Gdańska (2022)

Tomasz Olczyk

Postępująca degradacja naturalnego środowiska, stanowiącego jedyne miejsce ludzkiej egzystencji, wymaga od nas podjęcia szeregu niezwłocznych działań w celu jego ochrony. Istotnym z tego punktu widzenia zagadnieniem jest kształtowanie odpowiednich postaw ludzi od najwcześniejszych lat życia. Ważną rolę w tym procesie ma do odegrania edukacja szkolna. W tym edukacja ekologiczna w ramach nauki religii prowadzonej w szkołach publicznych, finansowanych przez państwo, na podstawie Konkordatu zawartego między Stolicą Apostolską a Rzecząpospolitą Polską.

10.26881/kg.2022.1.05

Cite

Citations (0)

rh-TSH (Thyrogen) aided radioiodine therapy in children and adolescents with DTC

Endocrine Abstracts (2014)

Daria Handkiewicz-Junak Józef Roskosz Tomasz Gawlik Tomasz Olczyk E Gubała

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Radioiodine therapy

10.1530/endoabs.35.oc1.5

Cite

Citations (0)

Changing Clinical Presentation of Pediatric Differentiated Thyroid Cancer in Poland: A Retrospective Cohort Study Spanning 45 Years

Thyroid (2024)

Aleksandra Kropińska Aleksandra Ledwoń Ewa Paliczka Cieslik Tomasz Olczyk Aleksandra Blewąska

Differentiated thyroid carcinoma (DTC) in children is uncommon; clinical presentation over recent decades is incompletely characterized.

Presentation (obstetrics)

10.1089/thy.2024.0109

Cite

Citations (1)

Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer

Annals of Nuclear Medicine (2021)

Aleksandra Ledwoń Ewa Paliczka-Cieślik Aleksandra Syguła Tomasz Olczyk Aleksandra Kropińska

In patients with differentiated thyroid carcinoma (DTC), serum thyroglobulin levels measured at the time of remnant ablation after thyroid hormone withdrawal were shown to have prognostic value for disease-free status. We sought to evaluate serial thyroglobulin measurements at the time of recombinant human thyroid-stimulating hormone (rhTSH)-aided iodine 131 (

Thyroglobulin

Radioiodine therapy

10.1007/s12149-021-01663-y

Cite

Citations (4)

Storytelling jako narzędzie marketingu politycznego – model

Studia Politologiczne (2017)

Jacek Wasilewski Tomasz Olczyk

Source

Cite

Citations (0)

Recurrence patterns in differentiated thyroid cancer (DTC) following adjuvant radioiodine therapy

Endokrynologia Polska (2024)

Aleksandra Ledwoń Aleksandra Kropińska Ewa Paliczka-Cieślik Aleksandra Blewąska Aleksandra Syguła

Introduction: With an increasing incidence of differentiated thyroid cancer (DTC) diagnosis, questions emerge about the optimal duration of follow-up for detecting recurrent disease and its outcomes. The objective of this retrospective research was to assess the clinical course of differentiated thyroid cancer after radioiodine adjuvant treatment in patients monitored over an extended period. Special attention was paid to the analysis of the time from treatment to recurrence. We also assessed patient outcomes after recurrence. Material and methods: A total of 650 patients with DTC after total/near-total thyroidectomy and adjuvant radioiodine post-recombinant human thyrotropin (post-rhTSH) stimulation were evaluated. All patients were followed up with neck ultrasound, serum thyroid-stimulating hormone (TSH), thyroglobulin (Tg), and antithyroglobulin antibody (anti-Tg) measurements at intervals of 6 to 18 months. Only structural recurrences were considered. They were defined as locoregional recurrence confirmed by biopsy or distant metastases [confirmed by computed tomography (CT) or magnetic resonance imaging (MRI), or abnormal foci on radioiodine scintigraphy or 18F-gluorodeoxyglucose positron emission tomography [18 F] FDG-PET scan], regardless of thyroglobulin (Tg) or anti-Tg levels. Results: The median follow-up was 12 years (5–15.5). Structural recurrence was observed in 47 out of 650 patients (7%). All but 3 locoregional recurrences were suitable for surgery. The median time to structural recurrence was 16 months, with only 9 (1.4%) patients presenting with recurrence after more than 60 months. At the time of the database closure, 601 patients (92%) had an excellent response, including 20 out of 47 (42%) patients with structural recurrence. Eighty-one out of 650 patients had died (12.5%) before the database closure. The median age at the last follow-up of the patients who died was 72 years (range 20–88). A second recurrence was diagnosed in 10 out of 650 patients (1.5%), corresponding to 21% (10 out of 47) of patients who had already experienced a recurrence. The median time from radioiodine (RAI) therapy to the second structural recurrence was 108 months. Conclusions: Structural recurrences in DTC are uncommon, with most patients showing a favourable response to treatment. Improved understanding of recurrence timing may define the duration of patient surveillance at reference centres that can be safely discontinued after 5 years in low- and intermediate-risk groups, as indicated in our study.

Radioiodine therapy

Adjuvant Therapy

Radioactive iodine

10.5603/ep.100533

Cite

Citations (0)

13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study

Thyroid Research (2009)

Daria Handkiewicz-Junak Józef Roskosz Kornelia Hasse-Lazar Sylwia Szpak‐Ulczok Zbigniew Puch

In 30-50% of patients with metastatic non-medullary thyroid cancer the metastases are not radioiodine-avid and so there is no effective treatment. Retinoids have demonstrated inhibition of thyroid tumor growth and induction of radioiodine uptake. The aim of our study was to assess benefits of the retinoic acid (RA) treatment to re-differentiate non-functional NMTC metastases.In this prospective study, 53 patients with radioiodine non avid metastatic disease (45) or hyperthyroglobulinemia (8) were treated with 13-cis-retinoic acid (13-CRA) [1.0 mg/kg/day over 1st week and then 1.5 mg/kg] for six weeks prior to I-131 treatment performed under rhTSH stimulation. The re-differentiating effect of RA was evaluated by serum thyroglobulin (Tg) monitoring before and after cessation of RA treatment and by qualitative analysis of iodine uptake on the post-therapeutic whole body scan (rxWBS).13-CRA induced radioiodine uptake in 9 (17%) of patients. In the univariate analysis neither the patient's gender, age, tumor histopathology, uptake in thyroid bed nor time since thyroid cancer diagnosis was associated with results of rxWBS.41 (77%) patients were evaluable for Tg response before and after to 13-CRA treatment. There was a statistically significant increase in median Tg level (60 v. 90 ng/ml, p < 0.05). There was no difference in Tg increase between scintigraphic responders and non-responders.13-CRA and RIT was repeated at least once in 8 of 9 scintigraphic responders. None of them showed tumor regression by radiological imaging within 12 months after the first treatment, 4/9 (44%) of them had disease progression.13-CRA treatment was well-tolerated. All but one patient complained of at least one side effect the most prevalent being lip dryness (98%). All side effects were transient and resolved within 2 weeks after 13-CRA cessation.Our results show that in patients with non-functional metastases from NMTC, 13-CRA is able to exert some re-differentiation effect by induction of radioiodine uptake in <20% of patients and increase of Tg serum level in about 30% of them. Nevertheless, this does not transfer into clinical benefit as it neither induces measurable tumor response nor prevents disease progression.

Thyroglobulin

Medullary Thyroid Cancer

Radioiodine therapy

Univariate analysis

10.1186/1756-6614-2-8

Cite

Citations (56)

Toxicity of tyrosine kinase inhibitors in the treatment of thyroid cancer - a 10-year experience resume

Endocrine Abstracts (2016)

Jolanta Krajewska Aleksandra Kukulska Ewa Paliczka-Cieślik Daria Handkiewicz-Junak Tomasz Gawlik

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Cancer Treatment

10.1530/endoabs.40.p6

Cite

Citations (0)